Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sells, imports and exports pharmaceuticals, clinical testing, and medical equipment for intractable diseases.

Otsuka Receives Fda Accelerated Approval For Voyxact (Sibeprenlimab-Szsi)

Sibeprenlimab Phase 3 Data Presented At American Society Of Nephrology Kidney Week 2025

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Otsuka Holdings (4578 JP)

Otsuka Receives Fda Accelerated Approval For Voyxact (Sibeprenlimab-Szsi)

Sibeprenlimab Phase 3 Data Presented At American Society Of Nephrology Kidney Week 2025

Consolidated Financial Results For The Nine-Month Period Ended September 30, 2025 [Ifrs]

(Progress Of Disclosure) Notice Of Completion Of Share Transfer Of Equity-Method Affiliate

Otsuka And Lundbeck Receive Complete Response Letter From U.S. Fda For Snda Of Rexulti

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)